| Tofacitinib | Tofacitinib | All tofacitinib |
---|---|---|---|
5Â mg BID | 10Â mg BID | ||
(N = 381) | (N = 105) | (N = 486) | |
Exposure, patient-years | 1111.7 | 328.2 | 1439.9 |
Patients with events per 100 patient-years (95Â % CI) | |||
 Adverse events | 307.5 (277.0, 340.4) | 311.8 (255.0, 377.5) | 308.4 (281.3, 337.4) |
 Serious adverse events | 11.2 (9.2, 13.5) | 9.2 (6.1, 13.3) | 10.7 (9.0, 12.6) |
 Serious infections | 3.2 (2.2, 4.5) | 3.7 (1.9, 6.4) | 3.3 (2.4, 4.4) |
 Herpes zoster (serious and non-serious) | 7.1 (5.5, 8.9) | 8.6 (5.6, 12.7) | 7.4 (6.0, 9.1) |
 Serious herpes zoster | 1.0 (0.5, 1.8) | 0.9 (0.2, 2.7) | 1.0 (0.5, 1.6) |
 Composite MACEa | 0.4 (0.1, 1.0) | 0.3 (0.0, 1.7) | 0.4 (0.1, 0.9) |
 Gastrointestinal perforations | 0 (0.0, 0.3) | 0 (0.0, 1.1) | 0 (0.0, 0.3) |
 All malignancy excluding NMSC | 1.4 (0.8, 2.3) | 0.3 (0.0, 1.7) | 1.2 (0.7, 1.9) |
 Mortality | 0.6 (0.3, 1.3) | 0.0 (0.0, 1.1) | 0.5 (0.2, 1.0) |